Industry Segment: Market Brief | Word Count: 145 Words
Attachment: bharat

India's leading vaccine-maker Bharat Biotech Limited is set to start human clinical trials for its COVID-19 vaccine candidate, Covaxin, which is India's first indigenously-developed vaccine against the coronavirus.

Covaxin was developed by Bharat Biotech, in collaboration with the Indian Council of Medical Research (ICMR) and National Institute of Virology (NIV). Drug Controller General of India (DCGI) on Monday granted Bharat Biotech approval to undertake the clinical trials, which are scheduled to start across India in July.